Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $7.2152W HIGH $31.00
Volume
1.63 K
Value Traded
98.35 K
Short % Float
21.5%
-3.43%Week
-26.93%1 Month
-9.9%3 Month
-50%6 Month
-97.98%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
16.17 M
EPS (TTM)
-4.71
P/E Ratio
-
Ent. Value
8.54 M
Total Shares
1.78 M
Float Shares
1.68 M
Insiders
5.59%
Institutions
49.63%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
PTN Catalyst Timeline
Dated clinical, regulatory and corporate events for Palatin Technologies, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Palatin Technologies, Inc.
814Total events
9Upcoming
185Tier-1 (high impact)
2007 to 2027Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Palatin to host conference call and webcast to discuss fiscal 2026 financial results
●Quarterly UpdateCorporate
Palatin reported fiscal year 2026 financial results and business update
▼Going ConcernCorporate
Substantial doubt exists about ability to continue as a going concern
●Trial InitiationTrial
Initiation of Phase 1 SAD/MAD trial for next-generation peptide MC4R agonist
obesitysource ↗
●IND SubmissionPL7737IND
PL7737 on track to enter clinical studies in first half of 2026
obesitysource ↗
◆Trial InitiationPL7737Trial
PL7737 on track to enter clinical evaluation in first half of 2026
obesitysource ↗
▲Partnership / LicensePL9643Corporate
Palatin recognized approximately $3.8 million in fiscal 2026 license revenue under Altanispac Labs agreement for PL9643
dry eye diseasesource ↗
▲Partnership / LicenseCorporate
Palatin recognized approximately $9.4 million in collaboration and license revenue related to Boehringer Ingelheim agreement during fiscal 2026
retinal diseasessource ↗
▼Equity OfferingCorporate
Closing of upsized $18.2 million public offering with full exercise of underwriters' over-allotment option
◆Poster PresentationbremelanotideFiledPresentation
Poster presentation of Phase 2 BMT-801 study data at ObesityWeek 2025
obesitysource ↗
◆Poster PresentationPL7737Presentation
Poster presentation of PL7737 preclinical data at ObesityWeek 2025
obesitysource ↗
▲Milestone PaymentCorporate
Received $6.5 million milestone payment from Boehringer Ingelheim for retinal disease collaboration
retinal diseasesource ↗
●IND SubmissionPL7737IND
IND submission planned for PL7737
obesity due to leptin receptor deficiencysource ↗
●IND SubmissionIND
IND applications for next-generation MC4R long-acting peptides and oral small molecules expected in Q4 2025
obesitysource ↗
●Trial InitiationTrial
Commencement of Phase 1 clinical studies for MC4R agonists targeted
general obesity, weight loss management, rare neuroendocrine and genetic diseasessource ↗
◆Topline ReadoutPL9643Clinical Data
Topline results expected for MELODY-2
dry eye disease (DED)source ↗
▲Milestone PaymentCorporate
Research milestone achieved under Boehringer Ingelheim collaboration triggers $6.5M payment
retinal diseasessource ↗
▲Partnership / LicenseCorporate
Strategic partnership with Boehringer Ingelheim to develop melanocortin receptor-targeted treatments for retinal diseases
retinal diseasessource ↗
▲Preclinical PoCPL7737Preclinical
Positive preclinical efficacy data for oral PL7737 in DIO rat model
obesitysource ↗
▲Partnership / LicenseCorporate
Ocular asset collaboration for preclinical glaucoma and retina programs
glaucoma and retinasource ↗
◆Partnership / LicensePL9643Corporate
Aim to finalize collaboration deal in second half of 2025
dry eye diseasesource ↗
◆Trial InitiationPL9643Trial
Patient enrollment for MELODY-2 could begin in second half of 2025
dry eye diseasesource ↗
▲Primary Endpoint MetbremelanotideFiledClinical Data
Phase 2 co-administration of Bremelanotide + Tirzepatide met primary endpoint with high statistical significance
obesitysource ↗
▲Full ResultsPL9643Clinical Data
PL9643 Phase 3 MELODY-1 responder analysis results reported
dry eye diseasesource ↗
◆Poster PresentationPL9654Presentation
Preclinical data on PL9654 and PL9655 presented at ARVO 2025
diabetic retinopathysource ↗
◆Poster PresentationPL9655Presentation
Preclinical data on PL9654 and PL9655 presented at ARVO 2025
diabetic retinopathysource ↗
▼Restructuring LayoffsCorporate
Common stock begins trading on OTC Pink Market under ticker PTNT
▲Poster PresentationPL9643Presentation
Poster presentation of updated Phase 3 MELODY-1 data at ARVO 2025
dry eye diseasesource ↗
▼Equity OfferingCorporate
Pricing of $11.5 million public offering with additional $11.5 million potential from milestone warrants
▼Restructuring LayoffsCorporate
NYSE American delisting notice received; stock suspended and transitioning to OTC Pink
▲Poster PresentationPL9588Presentation
Preclinical data for PL9588 presented at ARVO 2025
glaucomasource ↗
Past FDA Catalysts and PDUFA Decisions
How PTN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | next-generation oral MC4R selective agonist candidates | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D38 / 100
Pipeline Score
$8M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.5x
rNPV / MCap
Top 45%
Micro Cap(rank 297 of 658)
Percentile Rank
Palatin Technologies, Inc. faces pipeline headwinds (38/100), with $771M risk-adjusted pipeline value, led by bremelanotide in Obesity (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| bremelanotide Small moleculeMarketedNCT02333071 | Hypoactive Sexual Desire Disorder | Phase 3 | COMPLETED | 1,437 | Jun 30, 2017 |
Clinical Trial Results
Readouts, endpoints and source filings for every PTN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PL9643 | dry eye disease | Phase 3 | 2025-04-29 | 6 of 13 symptom endpoints showed a significantly higher percentage of patients in the PL9643 group achieving complete symptom resolution compared to placebo (p<0.05); Statistically significant symptom resolution by week 2; Continued improvement through week 12 with no plateauRead More | Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SPANA CARLDirector, Officer (President and CEO) | Disposition | -33 65,160 held | $11.77 | 07/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PTN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0 % | 670.00 K | 62.12 K | -11.25% ( -7.88 K) |
PTN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PTN ranks across every disease it competes in
Competitive Position is a premium feature
See how PTN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPTN News
PTN▼ -5.1%on this news
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
Palatin Technologies reported its fiscal year 2026 financial results, highlighting its focus on developing therapies for rare obesity disorders linked to the melanocortin 4 receptor (MC4R). The company plans to initiate Phase 1 studies for both injectable and oral MC4R selective agonists in 2027 and 2028. Despite generating $13.2 million in collaboration revenue, Palatin faces funding challenges to sustain its operations and development programs.
Read more →PTN▲ +5.8%on this news
Palatin to Begin Trading on Nasdaq Stock Exchange
Palatin Technologies, Inc. has announced its common stock will transition from the NYSE American to the Nasdaq Capital Market on May 29, 2026. The company expects this move to enhance visibility and trading liquidity, as well as provide greater exposure to institutional investors. Palatin is focused on developing novel therapeutics targeting the melanocortin receptor system, particularly for rare obesity disorders. Their innovative programs include injectable and oral MC4R selective agonists with anticipated IND submissions approaching in late 2026 and early 2027.
Read more →PTN▼ -16%on this newsshared move
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Technologies reported its fiscal third quarter 2026 financial results, highlighting advancements in its MC4R-based obesity programs. The company aims to submit IND applications for its MC4R selective peptide agonist and oral small molecule candidates in 2026 and 2027, respectively. Financially, Palatin recognized $3.9 million in collaboration revenue and reduced its net loss to $1.4 million, reflecting improved operational efficiency.
Read more →PTNPalatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Technologies has reported its financial results for the second quarter of fiscal year 2026, highlighting advancements in its MC4R-based obesity programs. The company is set to initiate clinical evaluations for its oral and long-acting peptide MC4R agonists. Despite a net loss of $7.3 million, Palatin has strengthened its balance sheet through a successful public offering and aims to address significant unmet medical needs in obesity treatment.
Read more →PTNPalatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Technologies reported strong financial results for the first quarter of fiscal year 2026, highlighting significant advancements in its obesity pipeline, particularly with the oral small molecule PL7737. The company successfully closed an $18.2 million public offering, enhancing its financial position and enabling continued development of its melanocortin-based therapies. Additionally, Palatin's stock has resumed trading on the NYSE American, marking a positive turnaround for the company.
Read more →PTN▲ +10.6%on this news· ran to +28% by day 3shared move
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Palatin Technologies announced the successful closing of an $18.2 million public offering, which included the full exercise of the underwriters' over-allotment option. The offering was well-received, with participation from key institutional investors and company executives. The proceeds will support the development of Palatin's obesity program and general corporate purposes. Additionally, the company has regained compliance with NYSE American listing standards.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
Palatin Technologies has announced the pricing of an upsized public offering, raising $15.8 million. The offering includes common stock and warrants, with participation from institutional investors and company executives. The funds will support the development of its obesity program and help regain compliance with NYSE American listing standards. The offering is expected to close on November 12, 2025.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Palatin Technologies, Inc. presented promising data on the melanocortin receptor (MC4R) agonist PL7737 at ObesityWeek® 2025, showing its potential for significant weight loss and safety in preclinical models. Additionally, a Phase II study indicated that combining MC4R agonists with tirzepatide could enhance weight management without new safety issues. Ongoing studies are set to lead to an IND submission and clinical trials in early 2026. The company is committed to advancing innovative therapies for obesity, particularly for rare genetic conditions.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
Palatin Technologies has achieved a significant milestone in its collaboration with Boehringer Ingelheim, earning a €5.5 million payment. This partnership focuses on developing innovative treatments targeting the melanocortin receptor system for retinal diseases, including diabetic retinopathy. The collaboration aims to address critical unmet medical needs in diabetes-related eye conditions.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Earns 5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
Palatin Technologies has achieved a research milestone in its collaboration with Boehringer Ingelheim, earning a payment of $6.5 million. The focus of this collaboration is on developing first-in-class treatments targeting melanocortin receptors for retinal diseases like diabetic retinopathy. Palatin aims to address significant unmet medical needs and has the potential for substantial future milestone payments and royalties under the partnership. This achievement reflects Palatin's strategy to enhance its pipeline of melanocortin receptor agonists through strategic collaborations.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Announces 1-for-50 Reverse Stock Split
Palatin Technologies has announced a 1-for-50 reverse stock split effective August 8, 2025. This action is taken to boost the market price of its shares, assisting compliance with NYSE American's Listing Qualifications. The adjusted shares will begin trading under the new ticker PTNTD on the OTCQB Market starting August 11, 2025. Shareholders approved this decision at the annual meeting held on July 25, 2025. The reverse stock split will consolidate shares and provide cash for any fractional shares.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity
Palatin Technologies announced promising preclinical efficacy data for their oral MC4R agonist PL7737 in obesity treatment. In rodent models, PL7737 demonstrated significant weight loss, both as a monotherapy and in combination with tirzepatide. The company plans to begin clinical trials in late 2025, with preliminary data expected in early 2026. Additionally, PL7737 has received orphan drug designation for treating leptin receptor deficiency-related obesity.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
Palatin Technologies reported strong operational results for Q3 of FY 2025, highlighting advancements in its obesity and ocular programs. The Phase 2 obesity study demonstrated effective weight reduction with a combination of therapies, while the Phase 3 ocular program achieved significant symptom resolution in dry eye patients. Despite these achievements, the company faces challenges such as the suspension and potential delisting from the NYSE American due to low stock price and reduced cash reserves. Moving forward, Palatin is focusing on securing funding to support ongoing operations and strategic initiatives.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Palatin Technologies presented promising preclinical data on its melanocortin agonists PL9654 and PL9655 for the treatment of diabetic retinopathy at the ARVO Annual Meeting. The findings indicate these compounds can resolve inflammation, stabilize the blood-retinal barrier, and protect retinal ganglion cells. Notably, both agents demonstrated efficacy through multiple administration routes, including topical delivery, suggesting significant potential for earlier treatment interventions. Ongoing development of these melanocortin receptor-targeting therapies is supported by the results, highlighting their innovative approach to managing diabetic retinopathy.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Technologies Announces Closing of Reduced Public Offering
Palatin Technologies, Inc. announced the closing of a reduced public offering, securing approximately $1.1 million in gross proceeds. The offering involved 7,324,119 shares of common stock along with accompanying warrants. The company plans to use the net proceeds primarily for working capital and general corporate purposes. This event marks a continued effort by the company to bolster its financial standing and support its development endeavors.
Read more →PTN▲ +11632.2%on this news· ran to +13428% by day 3shared move
Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
Palatin Technologies presented promising data on PL9643 during the Phase 3 MELODY-1 trial for dry eye disease at the ARVO 2025. The analysis showed that PL9643 could achieve full symptom resolution across multiple endpoints, demonstrating significant efficacy as early as two weeks into treatment. The therapy also exhibited a strong safety profile, with adverse events comparable to vehicle control. These findings suggest that PL9643 could be a first-in-class treatment, addressing unmet needs in the dry eye disease market.
Read more →PTN▼ -44.6%on this news· ran to +6394% by day 1shared move
Palatin Technologies Announces Transition to OTC Pink Following NYSE American Delisting Notice
Palatin Technologies announced it will transition to the OTC Pink Market after receiving a delisting notice from NYSE American due to the low selling price of its stock. Trading on the NYSE American has been suspended, and the company plans to appeal the delisting determination. CEO Carl Spana expressed disappointment but maintained confidence in the company's valuable assets and continued commitment to its business plan. Palatin has until May 14, 2025, to file its appeal.
Read more →About Palatin Technologies, Inc.
Headquarters4B CEDAR BROOK DRIVE, CRANBURY, NJ, 08512
BIOPHARMAWATCH ELITE PLUS
Trade the next PTN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime